School of Medicine
Showing 61-80 of 91 Results
-
Kilian M Pohl
Associate Professor (Research) of Psychiatry and Behavioral Sciences (Public Mental Health and Population Sciences)
Current Research and Scholarly InterestsThe foundation of the laboratory of Associate Professor Kilian M. Pohl, PhD, is computational science aimed at identifying biomedical phenotypes improving the mechanistic understanding, diagnosis, and treatment of neuropsychiatric disorders. The biomedical phenotypes are discovered by unbiased, machine learning-based searches across biological, neuroimaging, and neuropsychological data. This data-driven discovery currently supports the adolescent brain research of the NIH-funded National Consortium on Alcohol and NeuroDevelopment in Adolescence (NCANDA) and the Adolescent Brain Cognitive Development (ABCD), the largest long-term study of brain development and child health in the US. The laboratory also investigates brain patterns specific to alcohol use disorder and the human immunodeficiency virus (HIV) across the adult age range, and have advanced the understanding of a variety of brain diseases including schizophrenia, Alzheimer’s disease, glioma, and aging.
-
Michael Schneider
Adjunct Professor, Psych/Major Laboratories and Clinical & Translational Neurosciences Incubator
BioBret Schneider specializes in brain neuromodulation technologies for interventional psychiatry, neurology and regenerative medicine. He has designed, built and tested more than one hundred medical instruments, from computerized surgical navigation systems to implantable devices and biologics. As a technology company leader, he has founded and built several start-ups, including venture-capital-backed Cervel Neurotech Inc. Bret earned a BA cum laude from Washington University in St. Louis, an MD degree from Rush University in Chicago, and graduated a clinical residency in Psychiatry at UCLA. He subsequently completed a post-doctoral fellowship in neurosurgical stereotactic radiosurgery and a post-doctoral fellowship in Advanced Psychiatry, both at Stanford University. Presently, he is Chief Medical Officer for Zap Surgical Systems, Inc., where he is developing stereotactic radiosurgery as a method for precise, non-destructive, non-invasive modulation of dysfunctional brain circuits. Bret is also Adjunct Professor of Psychiatry and Neurosurgery at Stanford University. He maintains a clinical medical practice focused on repetitive transcranial magnetic stimulation (rTMS).
-
Nirao Shah
Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical Translational Neurosciences Incubator), of Neurobiology and, by courtesy, of Obstetrics and Gynecology
Current Research and Scholarly InterestsWe study how our brains generate social interactions that differ between the sexes. Such gender differences in behavior are regulated by sex hormones, experience, and social cues. Accordingly, we are characterizing how these internal and external factors control gene expression and neuronal physiology in the two sexes to generate behavior. We are also interested in understanding how such sex differences in the healthy brain translate to sex differences in many neuro-psychiatric illnesses.
-
David Spiegel
Jack, Lulu and Sam Willson Professor of Medicine
Current Research and Scholarly InterestsDr. Spiegel's research program involves mind/body interactions, including cancer progression, the response to traumatic stress, and the effect of hypnosis on the perception of pain and anxiety.
-
Edith Vioni Sullivan
Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical Translational Neurosciences Incubator)
Current Research and Scholarly InterestsApplication of neuroimaging modalities and component process analysis of cognitive, sensory, and motor functions to identify brain structural and functional mechanisms disrupted in diseases affecting the brain: alcohol use disorder, HIV infection, dementia, and normal aging from adolescence to senescence.
-
Alexander Eckehart Urban
Associate Professor of Psychiatry and Behavioral Sciences (Major Laboratories and Clinical Translational Neurosciences Incubator) and of Genetics
On Leave from 10/01/2021 To 08/31/2022Current Research and Scholarly InterestsComplex behavioral and neuropsychiatric phenotypes often have a strong genetic component. This genetic component is often extremely complex and difficult to dissect. The current revolution in genome technology means that we can avail ourselves to tools that make it possible for the first time to begin understanding the complex genetic and epigenetic interactions at the basis of the human mind.
-
Pablo Villoslada
Adjunct Professor, Psych/Major Laboratories and Clinical & Translational Neurosciences Incubator
BioPablo Villoslada received his MD at the University of Santiago de Compostela (Spain) in 1990. He completed the speciality in neurology in 1995 at the Hospital Vall d’Hebron (Spain) and the PhD in Neuroimmunology in 1996 at the Autonomous University of Barcelona (Spain). He moved to the University of California, San Francisco (US) as a postdoctoral fellow returning to Barcelona in 1998 and he worked as Assistant Professor of the University of Navarra from 2001 to 2008. He became Group leader of the Neuroimmunology group of the Institute of Biomedical Research August Pi Sunyer (IDIBAPS) – Hospital Clinic - University of Barcelona, Spain, in 2009. From 2014 to 2017 he became Adjunct Professor at the Department of Neurology at the University of California, San Francisco. From 2017 to 2018 he worked a Medical Director of Neuroinflammation at Genentech. Since October 2018 is adjunct professor at Stanford University. He is a serial entrepreneur, having founded Health Engineering (imaging software) and Bionure (drug development CNS), and being venture partner with Alta Life Sciences and Spire Bioventure. He joined the neurosciences team at Stanford University in October 2018.
Pablo Villoslada has been active in the Neurosciences and brain diseases research for more than 20 years contributing to the application of systems biology to neurological diseases, development of new therapies or biomarkers for Multiple Sclerosis and neurodegenerative diseases, and developing new neuroimaging technologies for monitoring brain diseases. He has published more than 170 scientific articles in journals in the field of neurology and has been granted 9 patents in biomarkers and new therapies for brain diseases. He has also obtained 5 EU grants and several others from international foundations.
